| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Report |
From the Institute of Molecular Cardiobiology, The Johns Hopkins University School of Medicine, Baltimore, Md.
Correspondence to Eduardo Marbán, MD, PhD, Chief of Cardiology, Institute of Molecular Cardiobiology, The Johns Hopkins University School of Medicine, 720 Rutland AveRoss 844, Baltimore, MD 21205. E-mail marban{at}jhmi.edu
Abstract
3-Hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitors (statins) can exert beneficial effects independently of serum cholesterol reduction by increasing the bioavailability of nitric oxide. However, it is unclear whether statins can exert such effects directly on cardiac myocytes and whether mitochondria are potential targets. Neonatal rat cardiac myocytes were cultured and subjected to oxidant stress (1 hour of 100 µmol/L H2O2). Mitochondrial membrane potential, a key determinant of cardiomyocyte viability, was assessed by flow cytometric analysis of tetramethylrhodamine ethyl ester (TMRE)loaded cells. Hydrogen peroxide significantly reduced mitochondrial membrane potential. Incubation of the cardiac myocytes in simvastatin (
1 µmol/L) 1 hour before peroxide exposure significantly attenuated the loss of TMRE fluorescence. This effect was inhibited by the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) or the ATP-sensitive mitochondrial potassium channel (mitoKATP) blocker 5-hydroxydecanoate. Simvastatin attenuates mitochondrial membrane depolarization after exposure to oxidant stress. These findings provide primary evidence that myocytes can act as triggers and effectors in the cardioprotective cascade of simvastatin therapy. These results bear implications of statin therapy as a potential clinical application of pharmacological preconditioning.
Key Words: mitochondria statins myocytes nitric oxide preconditioning
This article has been cited by other articles:
![]() |
S. P. Jones, N. E. Zachara, G. A. Ngoh, B. G. Hill, Y. Teshima, A. Bhatnagar, G. W. Hart, and E. Marban Cardioprotection by N-Acetylglucosamine Linkage to Cellular Proteins Circulation, March 4, 2008; 117(9): 1172 - 1182. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Hauck, C. Harms, D. Grothe, J. An, K. Gertz, G. Kronenberg, R. Dietz, M. Endres, and R. von Harsdorf Critical Role for FoxO3a-Dependent Regulation of p21CIP1/WAF1 in Response to Statin Signaling in Cardiac Myocytes Circ. Res., January 5, 2007; 100(1): 50 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. Patel, B. P. Head, H. N. Petersen, I. R. Niesman, D. Huang, G. J. Gross, P. A. Insel, and D. M. Roth Protection of adult rat cardiac myocytes from ischemic cell death: role of caveolar microdomains and {delta}-opioid receptors Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H344 - H350. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D.M. Engelmann and J. H. Svendsen Inflammation in the genesis and perpetuation of atrial fibrillation Eur. Heart J., October 2, 2005; 26(20): 2083 - 2092. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ito, T. Adachi, D. R. Pimentel, Y. Ido, and W. S. Colucci Statins Inhibit {beta}-Adrenergic Receptor-Stimulated Apoptosis in Adult Rat Ventricular Myocytes via a Rac1-Dependent Mechanism Circulation, July 27, 2004; 110(4): 412 - 418. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Bae, E. Bassenge, K.-Y. Kim, Y.-C. Synn, k.-R. Park, and M. Schwemmer Effects of Low-Dose Atorvastatin on Vascular Responses in Patients Undergoing Percutaneous Coronary Intervention With Stenting Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 185 - 192. [Abstract] [PDF] |
||||
![]() |
C. Patterson, M. S. Runge, and N. Madamanchi Younger Than Yesterday: Is Vascular Senescence a Two-Way Street? Circ. Res., April 2, 2004; 94(6): 703 - 705. [Full Text] [PDF] |
||||
![]() |
K. Kumagai, H. Nakashima, and K. Saku The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model Cardiovasc Res, April 1, 2004; 62(1): 105 - 111. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |